Cite item


Artemisinin is a sesquiterpene lactone isolated from the aerial part of sweet wormwood (Artemisia annua L.) in the 1970s. Based on its derivatives, the most effective medicines for the treatment of malaria have been created and are widely used. Over the past two decades, numerous in vitro and in vivo studies have been performed. They have shown the anticancer activity of these drugs in relation to certain cancer cell lines. The aim of the study is the review the scientific information on the clinical cases and the results of clinical trials carried out using drugs based on artemisinin derivatives. Material and methods. The study was conducted with the use of information search (PubMed, ScholarGoogle,) and library databases (Cochrane, eLibrary, Cyberleninca), as well as ResearchGate application for semantic search. Results and discussion. It has been established that the largest number of known clinical cases and completed clinical studies is associated with the study of the anticancer activity of one of the artemisinin derivatives - artesunate. The data obtained by various research groups do not yet allow us to speak of a pronounced activity of the latter. However, the facts of prolonging the life of patients, improving its quality, increasing control over the disease have been established. Conclusion. The published data of clinical cases and clinical studies performed for the period from 2001 to 2016, instill restrained optimism about the prospect of using drugs based on some artemisinin derivatives in oncology.

About the authors

D. A. Konovalov

Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University of the Ministry of Health of Russia

Email: d.a.konovalov@pmedpharm.ru

A. A. Khamilonov

Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University of the Ministry of Health of Russia

Email: spartan400@yandex.ru

O. M. Shevchuk

Nikitsky Botanic Garden

Email: oksana_shevchuk1970@mail.ru

L. A. Logvinenko

Nikitsky Botanic Garden

Email: fake@neicon.ru


  1. Cancer – World Health Organization // WHO media centre: cancer, fact sheet, 12 September 2018. Режим доступа: http://www.who.int/mediacentre/factsheets/fs297/en/. (accessed: 03.08.2018).
  2. Newman D.J., Cragg G.M. Natural products as sources of new drugs from 1981 to 2014 // J. Nat. Prod. – 2016. – Vol. 79. – P. 629–661. doi: 10.1021/acs.jnatprod.5b01055.
  3. Kinghorn A.D., de Blanco E.J.C., Lucas D.M., Rakotondraibe H.L., Orjala J., Soejarto D.D., Oberlies N.H., Pearce C.J., Wani M.C., Stockwell B.R., Burdette J.E., Swanson S.M., Fuchs J.R., Phelps M.A., Xu L., Zhang X., Shen Y.Y. Discovery of Anticancer Agents of Diverse Natural Origin // Anticancer Res. – 2016. – Vol. 36, №11. – P. 5623–5637. doi: 10.21873/anticanres.11146.
  4. Tariq A., Sadia S., Pan K., Ullah I., Mussarat S., Sun F., Xiong Q. A systematic review on ethnomedicines of anticancer plants // Phytotherapy Research. – 2017. – Vol. 31, № 2. – P. 202–264. doi: 10.1002/ptr.575.
  5. Akhtar M.S., Swamy M.K. Anticancer Plants: Clinical Trials and Nanotechnology. 2018.
  6. Akhtar M.S., Swamy M.K. Anticancer Plants: Natural Products and Biotechnological Implements. 2018.
  7. Butler M.S., Robinson A.A.B., Cooper M.A. Natural product and natural product derived drugs in clinical trials // Nat. Prod. Rep. – 2014. – Vol. 31, №11. – P. 1612–1661. doi: 10.1039/c4np00064a.
  8. Crespo-Ortiz M.P., Wei M.Q. Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug // Journal of Biomedicine and Biotechnology. – 2012. – Vol. 2012, – Р. 18. doi: 10.1155/2012/247597.
  9. Efferth Th. Artemisinin – Second Career as Anticancer Drug? // World J. Tradit. Chin. Med. – 2015. – Vol. 1, №4. – P. 2–25. doi: 10.1016/j.tips.2008.07.004.
  10. Ren Y., Yu J., Kinghorn A.D. Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones // Current Medicinal Chemistry. – 2016. – Vol. 23, № 23. – P. 2397–2420.
  11. Bhaw-Luximon A., Jhurry D. Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives // Cancer chemotherapy and pharmacology. – 2017. – Vol. 79, № 3. – P. 451–466. doi: 10.1007/s00280-017-3251-7.
  12. Efferth T. Cancer combination therapies with artemisinin-type drugs // Biochemical pharmacology. – 2017. – Vol.139. – P. 56–70. doi: 10.1016/j.bcp.2017.03.019.
  13. Konstat-Korzenny E., Ascencio-Aragón J., Niezen-Lugo S., Vázquez-López R. Artemisinin and its synthetic derivatives as a possible therapy for cancer // Medical Sciences. – 2018. – Vol. 6, – №1. – P. 19–28. doi: 10.3390/medsci6010019.
  14. Abba M.L., Patil N., Leupold J.H., Saeed M.E., Efferth T., Allgayer H. Prevention of carcinogenesis and metastasis by Artemisinin-type drugs // Cancer letters. – 2018. – Vol. 429. – P. 11-18. doi: 10.1016/j.canlet.2018.05.008.
  15. O’Neill P.M., Barton V.E., Ward St.A. The Molecular Mechanism of Action of Artemisinin. The Debate Continues // Molecules. – 2010. – Vol. 15. – P. 1705–1721. doi: 10.3390/molecules15031705.
  16. Wong Y.K., Xu C., Kalesh K.A., He Y., Lin Q., Wong W.F., Wang, J. Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action // Medicinal research reviews. – 2017. – Vol. 37, № 6. – P. 1492–1517. doi: 10.4103/2141-9248.153609.
  17. Tu Y. From Artemisia Annua L. to Artemisinins: The Discovery and Development of Artemisinins and Antimalarial Agents. – Academic Press, Cambridge 2017. 468 pp. doi: 10.1002/cmdc.201700632.
  18. Nakase I., Lai H., Singh N.P., Sasaki T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation // International Journal of Pharmaceutics. – 2008 Apr 16; – Vol. 354. №1–2. – P. 28–33.
  19. Li Q, Weina PJ, Milhous WK. Pharmacokinetic and pharmacodynamic profiles of rapidacting artemisinins in the antimalarial therapy // Curr Drug Ther. – 2007. – Vol. 2, № 3. – Р. 210–223. doi: 10.2174/157488507781695649.
  20. Aftab T., Ferreira J.F.S., Khan M.M.A., Naeem M. Artemisia annua – Pharmacology and Biotechnology. Springer Verlag Berlin Heidelberg. 2014.
  21. Belafsky P.C. Laryngeal Cancer. San Diego Center for Voice and Swallowing Disorders. Режим доступа: http://www.sandiegovoice.org/larynxca.html.
  22. Singh N.P., Verma K.B. Case report of a laryngeal squamous cell carcinoma treated with artesunate. // Arch Oncol. – 2002. – Vol.10, – №4. – P.279–280.
  23. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics // CA Cancer J Clin. – 2018 Jan; – Vol. 68, №1 – Р. 7–30. doi: 10.3322/caac.21332.
  24. Berger T.G., Dieckmann D., Efferth T., Schultz E.S., Funk J.O., Baur A., Schuler G. Artesunate in the treatment of metastatic uveal melanoma – first experiences. // Oncol Rep. – 2005. – Vol. 14, № 6. – Р. 1599–1603.
  25. Singh N.P., Panwar V.K. Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther. – 2006. – Vol. 5, № 4. – Р. 391–394.
  26. Zhang Z.Y., Yu S.Q., Miao L.Y., Huang X.Y., Zhang X.P., Zhu Y.P., Xia X.H., Li D.Q. Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: A randomized controlled trial // J Chin Integr Med / Zhong Xi Yi Jie He Xue Bao. – 2008. – Vol. 6, № 2. – Р. 134–138.
  27. Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR. The anti-malarial artesunate is also active against cancer. // Int J. Oncol. – 2001. – Vol. 18, №4. – P. 767–773.
  28. Jansen F.H., Adoubi I., KC J.C., Cnodder D.E.T., Jansen N., Tschulakow A., Efferth T. First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. Anticancer Res. – 2011. – Vol. 31, № 12, – Р. 4417–4422.
  29. GLOBOCAN (2012). Estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer; World Health Organization (WHO).
  30. Mao H., Gu H., Qu X., Sun J., Song B., Gao W., Liu J., Shao Q. Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro // Int. J. Mol. Med. – 2013. – Vol. 31, № 1, – P. 213–218. doi: 10.3892/ijmm.2012.1176.
  31. Ericsson Th., Blank A., von Hagens C., Ashton M., Äbelö A. Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer // Eur. J. Clin. Pharmacol. – 2014. – Vol. 70. P. 1453–1463. doi: 10.1007/s00228-014-1754-2.
  32. König M., von Hagens C., Hoth S., Baumann I., Walter-Sack I., Edler L., Sertel S. Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study // Cancer Chemother Pharmacol. – 2016. – Vol. 77, №2. – P. 413–427. doi: 10.1007/s00280-016-2960-7.
  33. Hagens C., Walter-Sack I., Goeckenjan M., Osburg J., Storch-Hagenlocher B., Sertel S., Efferth T. Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). Breast cancer research and treatment. – 2017. – Vol. 164, № 2, – Р. 359–369. doi: 10.1007/s10549-017-4261-1.
  34. Michaelsen Fr.W., Saeed M.E.M., Schwarzkopf J., Efferth Th. Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma // Phytomedicine. – 2015. Dec 15; – Vol. 22, №14. – Р. 1223–31. doi: 10.1016/j.phymed.2015.11.001.
  35. Krishna S., Ganapathi S., Ster I.C., Saeed M.E., Cowan M., Finlayson C., Kovacsevics H., Jansen H., Kremsner P.G., Efferth T., Kumar D. A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer // EBioMed. – 2015 Jan; – Vol. 2, №1. – Р. 82–90. doi: 10.1016/j.ebiom.2014.11.010.
  36. Deeken J.F., Wang H., Hartley M., Cheema A.K., Smaglo B., Hwang, J.J., Liu S. (2018). A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies // Cancer chemotherapy and pharmacology. – 2018. – Vol. 81, № 3. – Р. 587–596.

Copyright (c) 2018 Konovalov D.A., Khamilonov A.A., Shevchuk O.M., Logvinenko L.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 67428 от 13.10.2016. 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies